Go Pro
NASDAQ:MBOT

Microbot Medical Q1 2026 Earnings Report

Microbot Medical logo
$1.48 -0.02 (-1.33%)
As of 08/28/2026 04:00 PM Eastern

Microbot Medical EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$190.00 thousand
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Microbot Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Microbot Medical Earnings Headlines

HC Wainwright Cuts Earnings Estimates for Microbot Medical
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

View Microbot Medical Profile